Pathological chemotherapy response score predicts survival in patients with advanced ovarian cancer receiving neoadjuvant chemotherapy: an individual patient meta-analysis

Paul Cohen; Steffen Bohm; Aime  Powell; Tarek Meniawy; Colin Stewart; Max Bulsara; C. Blake Gilks; Naveena Singh

doi:10.1136/00009577-201809002-00001

Abstract

Background and Aims: The chemotherapy response score (CRS) is recommended for uniform recording of histological tumor response to neoadjuvant chemotherapy (NACT) in high-grade serous ovarian carcinoma (HGSC)1. CRS reproducibly stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response2. Single-center studies have shown an association between CRS and progression-free survival (PFS) but not overall survival (OS)3-6. Our objective was to perform an individual patient data (IPD) meta-analysis for further prognostic validation. Methods: Data from 14 centers in 10 countries were analysed. Eligibility criteria were: stage III/IV HGSC, 3/4 NACT cycles, locally determined CRS, minimum 6-month follow-up, known survival outcomes. Meta-analysis techniques for IPD with random effects were used to derive combined odds ratios (ORs). Results: Data from 813 patients fulfilled eligibility criteria. 486 (59.8%) and 327 (40.2%) patients had stages III and IV disease respectively. Median follow up was 28 months. Median OS was 28.0 months. 621 (76%) and 362 (45%) patients relapsed and/or died. 549 patients (67.5%) showed CRS1/2 and 264 (32.5%) showed CRS3. Adjusting for age, stage and residual disease, PFS was significantly improved (21.9 vs. 14.5 months, OR 0.5, 95% CI 0.45–0.67, p =

Original language	English
Pages	1-1258
Number of pages	1258
DOIs	https://doi.org/10.1136/00009577-201809002-00001
Publication status	Published - Sept 2018
Event	17th Biennial Meeting of the International Gynecologic Cancer Society - Kyoto, Japan Duration: 14 Sept 2018 → 16 Sept 2018

Conference

Conference	17th Biennial Meeting of the International Gynecologic Cancer Society
Country/Territory	Japan
City	Kyoto
Period	14/09/18 → 16/09/18

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/00009577-201809002-00001

https://ijgc.bmj.com/content/28/Suppl_2/1

Cite this

Cohen, P., Bohm, S., Powell, A., Meniawy, T., Stewart, C., Bulsara, M., Gilks, C. B., & Singh, N. (2018). Pathological chemotherapy response score predicts survival in patients with advanced ovarian cancer receiving neoadjuvant chemotherapy: an individual patient meta-analysis. 1-1258. Abstract from 17th Biennial Meeting of the International Gynecologic Cancer Society, Kyoto, Japan. https://doi.org/10.1136/00009577-201809002-00001

@conference{fa51ec7c713f43c1bce3ae6c4c73b380,

title = "Pathological chemotherapy response score predicts survival in patients with advanced ovarian cancer receiving neoadjuvant chemotherapy: an individual patient meta-analysis",

abstract = "Background and Aims: The chemotherapy response score (CRS) is recommended for uniform recording of histological tumor response to neoadjuvant chemotherapy (NACT) in high-grade serous ovarian carcinoma (HGSC)1. CRS reproducibly stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response2. Single-center studies have shown an association between CRS and progression-free survival (PFS) but not overall survival (OS)3-6. Our objective was to perform an individual patient data (IPD) meta-analysis for further prognostic validation. Methods: Data from 14 centers in 10 countries were analysed. Eligibility criteria were: stage III/IV HGSC, 3/4 NACT cycles, locally determined CRS, minimum 6-month follow-up, known survival outcomes. Meta-analysis techniques for IPD with random effects were used to derive combined odds ratios (ORs). Results: Data from 813 patients fulfilled eligibility criteria. 486 (59.8%) and 327 (40.2%) patients had stages III and IV disease respectively. Median follow up was 28 months. Median OS was 28.0 months. 621 (76%) and 362 (45%) patients relapsed and/or died. 549 patients (67.5%) showed CRS1/2 and 264 (32.5%) showed CRS3. Adjusting for age, stage and residual disease, PFS was significantly improved (21.9 vs. 14.5 months, OR 0.5, 95% CI 0.45–0.67, p = ",

author = "Paul Cohen and Steffen Bohm and Aime Powell and Tarek Meniawy and Colin Stewart and Max Bulsara and Gilks, {C. Blake} and Naveena Singh",

year = "2018",

month = sep,

doi = "10.1136/00009577-201809002-00001",

language = "English",

pages = "1--1258",

note = " 17th Biennial Meeting of the International Gynecologic Cancer Society ; Conference date: 14-09-2018 Through 16-09-2018",

}

Cohen, P, Bohm, S, Powell, A, Meniawy, T, Stewart, C, Bulsara, M, Gilks, CB & Singh, N 2018, 'Pathological chemotherapy response score predicts survival in patients with advanced ovarian cancer receiving neoadjuvant chemotherapy: an individual patient meta-analysis', 17th Biennial Meeting of the International Gynecologic Cancer Society, Kyoto, Japan, 14/09/18 - 16/09/18 pp. 1-1258. https://doi.org/10.1136/00009577-201809002-00001

Pathological chemotherapy response score predicts survival in patients with advanced ovarian cancer receiving neoadjuvant chemotherapy: an individual patient meta-analysis. / Cohen, Paul; Bohm, Steffen; Powell, Aime et al.
2018. 1-1258 Abstract from 17th Biennial Meeting of the International Gynecologic Cancer Society, Kyoto, Japan.

Research output: Contribution to conference › Abstract › peer-review

TY - CONF

T1 - Pathological chemotherapy response score predicts survival in patients with advanced ovarian cancer receiving neoadjuvant chemotherapy

T2 - 17th Biennial Meeting of the International Gynecologic Cancer Society

AU - Cohen, Paul

AU - Bohm, Steffen

AU - Powell, Aime

AU - Meniawy, Tarek

AU - Stewart, Colin

AU - Bulsara, Max

AU - Gilks, C. Blake

AU - Singh, Naveena

PY - 2018/9

Y1 - 2018/9

N2 - Background and Aims: The chemotherapy response score (CRS) is recommended for uniform recording of histological tumor response to neoadjuvant chemotherapy (NACT) in high-grade serous ovarian carcinoma (HGSC)1. CRS reproducibly stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response2. Single-center studies have shown an association between CRS and progression-free survival (PFS) but not overall survival (OS)3-6. Our objective was to perform an individual patient data (IPD) meta-analysis for further prognostic validation. Methods: Data from 14 centers in 10 countries were analysed. Eligibility criteria were: stage III/IV HGSC, 3/4 NACT cycles, locally determined CRS, minimum 6-month follow-up, known survival outcomes. Meta-analysis techniques for IPD with random effects were used to derive combined odds ratios (ORs). Results: Data from 813 patients fulfilled eligibility criteria. 486 (59.8%) and 327 (40.2%) patients had stages III and IV disease respectively. Median follow up was 28 months. Median OS was 28.0 months. 621 (76%) and 362 (45%) patients relapsed and/or died. 549 patients (67.5%) showed CRS1/2 and 264 (32.5%) showed CRS3. Adjusting for age, stage and residual disease, PFS was significantly improved (21.9 vs. 14.5 months, OR 0.5, 95% CI 0.45–0.67, p =

AB - Background and Aims: The chemotherapy response score (CRS) is recommended for uniform recording of histological tumor response to neoadjuvant chemotherapy (NACT) in high-grade serous ovarian carcinoma (HGSC)1. CRS reproducibly stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response2. Single-center studies have shown an association between CRS and progression-free survival (PFS) but not overall survival (OS)3-6. Our objective was to perform an individual patient data (IPD) meta-analysis for further prognostic validation. Methods: Data from 14 centers in 10 countries were analysed. Eligibility criteria were: stage III/IV HGSC, 3/4 NACT cycles, locally determined CRS, minimum 6-month follow-up, known survival outcomes. Meta-analysis techniques for IPD with random effects were used to derive combined odds ratios (ORs). Results: Data from 813 patients fulfilled eligibility criteria. 486 (59.8%) and 327 (40.2%) patients had stages III and IV disease respectively. Median follow up was 28 months. Median OS was 28.0 months. 621 (76%) and 362 (45%) patients relapsed and/or died. 549 patients (67.5%) showed CRS1/2 and 264 (32.5%) showed CRS3. Adjusting for age, stage and residual disease, PFS was significantly improved (21.9 vs. 14.5 months, OR 0.5, 95% CI 0.45–0.67, p =

U2 - 10.1136/00009577-201809002-00001

DO - 10.1136/00009577-201809002-00001

M3 - Abstract

SP - 1

EP - 1258

Y2 - 14 September 2018 through 16 September 2018

ER -